296 related articles for article (PubMed ID: 35065158)
1. Immunostimulation of tumor microenvironment by targeting tumor-associated macrophages with hypoxia-responsive nanocomplex for enhanced anti-tumor therapy.
Kang Y; Lim J; Saravanakumar G; Kim J; Park M; Im S; Kim WJ
J Control Release; 2022 Mar; 343():78-88. PubMed ID: 35065158
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
[TBL] [Abstract][Full Text] [Related]
3. Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumors.
Anfray C; Varela CF; Ummarino A; Maeda A; Sironi M; Gandoy S; Brea J; Loza MI; León S; Calvo A; Correa J; Fernandez-Megia E; Alonso MJ; Allavena P; Crecente-Campo J; Andón FT
Front Immunol; 2023; 14():1334800. PubMed ID: 38259462
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
5. Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy.
Huang L; Xu R; Li W; Lv L; Lin C; Yang X; Yao Y; Saw PE; Xu X
Acta Biomater; 2023 May; 162():98-109. PubMed ID: 36931417
[TBL] [Abstract][Full Text] [Related]
6. Efficient TNBC immunotherapy by dual reprogramming tumor-infiltrating dendritic cells and tumor-associated macrophages with stimulus-responsive miR155 nanocomplexes.
Jing Z; Li Y; Song J; Zang X
Int J Biol Macromol; 2023 Dec; 253(Pt 3):126912. PubMed ID: 37722648
[TBL] [Abstract][Full Text] [Related]
7. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
8. Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer.
Chen Y; Gong L; Cao Y; Liu Z; Wang Y; Cheng H; Feng Y; Yao S; Yin Y; Wu Z; Huang Z
J Control Release; 2024 Feb; 366():395-409. PubMed ID: 38184235
[TBL] [Abstract][Full Text] [Related]
9. Self-Assembled Nanoparticles from the Amphiphilic Prodrug of Resiquimod for Improved Cancer Immunotherapy.
Li JX; Shu N; Zhang YJ; Tong QS; Wang L; Zhang JY; Du JZ
ACS Appl Mater Interfaces; 2024 May; 16(20):25665-25675. PubMed ID: 38735053
[TBL] [Abstract][Full Text] [Related]
10. Nanomaterials-Involved Tumor-Associated Macrophages' Reprogramming for Antitumor Therapy.
Li SL; Hou HY; Chu X; Zhu YY; Zhang YJ; Duan MD; Liu J; Liu Y
ACS Nano; 2024 Mar; 18(11):7769-7795. PubMed ID: 38420949
[TBL] [Abstract][Full Text] [Related]
11. Injectable shear-thinning polylysine hydrogels for localized immunotherapy of gastric cancer through repolarization of tumor-associated macrophages.
Yang Y; Yang Y; Chen M; Chen J; Wang J; Ma Y; Qian H
Biomater Sci; 2021 Sep; 9(19):6597-6608. PubMed ID: 34582523
[TBL] [Abstract][Full Text] [Related]
12. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy.
Gao J; Liang Y; Wang L
Front Immunol; 2022; 13():888713. PubMed ID: 35844605
[TBL] [Abstract][Full Text] [Related]
13. Polymer-polymer conjugation to fabricate multi-block polymer as novel drug carriers: poly(lactic acid)-poly(ethylene glycol)-poly(L-lysine) to enhance paclitaxel target delivery.
Liu Y; Liu C; Li M; Liu F; Feng L; Zhang L; Zhang N
J Biomed Nanotechnol; 2014 Jun; 10(6):948-58. PubMed ID: 24749390
[TBL] [Abstract][Full Text] [Related]
14. Reprogramming Hypoxic Tumor-Associated Macrophages by Nanoglycoclusters for Boosted Cancer Immunotherapy.
Zhao YD; An HW; Mamuti M; Zeng XZ; Zheng R; Yang J; Zhou W; Liang Y; Qin G; Hou DY; Liu X; Wang H; Zhao Y; Fang X
Adv Mater; 2023 Jun; 35(24):e2211332. PubMed ID: 36971342
[TBL] [Abstract][Full Text] [Related]
15. Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy.
Wang Y; Yu J; Luo Z; Shi Q; Liu G; Wu F; Wang Z; Huang Y; Zhou D
Adv Mater; 2021 Oct; 33(39):e2103497. PubMed ID: 34387375
[TBL] [Abstract][Full Text] [Related]
16. Repolarizing Tumor-Associated Macrophages and inducing immunogenic cell Death: A targeted liposomal strategy to boost cancer immunotherapy.
Li C; Wang L; Li Z; Li Z; Zhang K; Cao L; Wang Z; Shen C; Chen L
Int J Pharm; 2024 Feb; 651():123729. PubMed ID: 38142016
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages.
Li X; Guo X; Ling J; Tang Z; Huang G; He L; Chen T
Nanoscale; 2021 Mar; 13(9):4705-4727. PubMed ID: 33625411
[TBL] [Abstract][Full Text] [Related]
18. Protein-Crowned Micelles for Targeted and Synergistic Tumor-Associated Macrophage Reprogramming to Enhance Cancer Treatment.
Sun JH; Liang X; Cai M; Yan L; Chen Z; Guo L; Jing L; Wang Y; Zhou D
Nano Lett; 2022 Jun; 22(11):4410-4420. PubMed ID: 35575719
[TBL] [Abstract][Full Text] [Related]
19. The role of the hypoxia-Nrp-1 axis in the activation of M2-like tumor-associated macrophages in the tumor microenvironment of cervical cancer.
Chen XJ; Wu S; Yan RM; Fan LS; Yu L; Zhang YM; Wei WF; Zhou CF; Wu XG; Zhong M; Yu YH; Liang L; Wang W
Mol Carcinog; 2019 Mar; 58(3):388-397. PubMed ID: 30362630
[TBL] [Abstract][Full Text] [Related]
20. Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction.
Zhao M; Li J; Liu J; Xu M; Ji H; Wu S; Chen D; Hu H
J Control Release; 2021 Jul; 335():320-332. PubMed ID: 34062192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
